Candidal Vulvovaginitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for candidal vulvovaginitis. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2042. Daily refresh.

1
Approved drugs
1
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Candidal Vulvovaginitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bayer AG 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating candidal vulvovaginitis. Each bar = one year. Y-axis scaled to peak year (1 patents).

No expiries in next 15 years.

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lotrimin
clotrimazole
 Bayer AG 1 75 — 2042-05-26

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12246006 Lotrimin method of use 75 2042-05-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12246006 Lotrimin method of use 75 2042-05-26

Related